AULS.F Stock Overview

An investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. More details

AULS.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 80.8% below our estimate of its fair value

Became profitable this year

Risk Analysis

Shares are highly illiquid

Earnings have declined by 19.3% per year over past 5 years

Does not have a meaningful market cap ($405M)

Large one-off items impacting financial results

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Austar Lifesciences Limited Competitors

Champions Oncology

NasdaqCM:CSBR

US$79.6m

Niagen Bioscience

NasdaqCM:NAGE

US$686.8m

Sotera Health

NasdaqGS:SHC

US$3.7b

Precision BioSciences

NasdaqCM:DTIL

US$53.5m

Price History & Performance

Summary of share price highs, lows and changes for Austar Lifesciences
Historical stock prices
Current Share Price	HK$0.07
52 Week High	HK$0.07
52 Week Low	HK$0.005
Beta	1.55
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-96.37%

Recent updates

Shareholder Returns

	AULS.F	US Life Sciences	US Market
7D	0%	-2.7%	1.2%
1Y	n/a	-28.0%	7.7%

Return vs Industry: Insufficient data to determine how AULS.F performed against the US Life Sciences industry.

Return vs Market: Insufficient data to determine how AULS.F performed against the US Market.

Price Volatility

Is AULS.F's price volatile compared to industry and market?
AULS.F volatility
AULS.F Average Weekly Movement	n/a
Life Sciences Industry Average Movement	11.0%
Market Average Movement	7.9%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	4.1%

Stable Share Price: AULS.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine AULS.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1991	1,445	Mars Ho	www.austar.com.hk

Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. The company operates through Integrated Process and Packaging Equipment & Systems (IPS); Consulting, Digitalization and Construction (CDC); and Life Science Equipment and Consumables (SIC) segments. It also offers clean utility and bioprocess equipment, clean room, automation control and monitor system; bioprocess equipment consumables, and laboratory solutions.

Austar Lifesciences Limited Fundamentals Summary

How do Austar Lifesciences's earnings and revenue compare to its market cap?
AULS.F fundamental statistics
Market cap	US$52.18m
Earnings (TTM)	US$2.23m
Revenue (TTM)	US$207.66m

23.4x

P/E Ratio

0.3x

P/S Ratio

Is AULS.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AULS.F income statement (TTM)
Revenue	CN¥1.50b
Cost of Revenue	CN¥1.20b
Gross Profit	CN¥301.22m
Other Expenses	CN¥285.14m
Earnings	CN¥16.08m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.031
Gross Margin	20.08%
Net Profit Margin	1.07%
Debt/Equity Ratio	44.6%

How did AULS.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/07 18:45
End of Day Share Price	2025/02/19 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Austar Lifesciences Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Milo Liu	BOCOM International Securities Limited
Forrest Chan	CCB International Securities Limited
Tsz Man Chan	KGI Securities Co. Ltd.